TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04724486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study: NCT00131560

Intervention type: GENETIC
Group type: OTHER
Intervention: VRX496-Modified Autologous T cells
Description: Genetic: Anti-HIV antisense
Study: NCT03053492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duck Duck Punch Play
Description: The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available Game Play
Description: The behavioral intervention will include playing a hands-free video game available off-the-shelf.
Study: NCT03572829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
Study: NCT02522338

Intervention type: DRUG
Group type: OTHER
Intervention: iohexol
Description: 10 ml de l'iohexol (300 mgI/ml)
Study: NCT02696278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lesson about vegetables
Description: During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lesson about vegetables
Description: During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hummus
Description: During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
Study: NCT04724486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study: NCT02601001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Omecamtiv mecarbil tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Omecamtiv mecarbil tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT02229864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm
Study: NCT04018287

Intervention type: OTHER
Intervention: HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)
Description: HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation.

Intervention type: OTHER
Intervention: HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)
Description: HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation.
Study: NCT02231216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhinoseptoplasty
Description: Rhinoseptoplasty without turbinectomy procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty
Description: Rhinoseptoplasty without turbinectomy procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial turbinectomy
Description: After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic partial turbinectomy
Description: Endoscopy to medial dislocation of the inferior turbinate with instrument
Study: NCT02255591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-adrenaline added gadolinium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-adrenaline added gadolinium.
Study: NCT03488940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hours group
Description: Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16-hours group
Description: Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.
Study: NCT01080963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
Study: NCT02342587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
Study: NCT02796443

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy (LC)
Description: Removal of the gallbladder via a minimally invasive approach

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy (LC)
Description: Removal of the gallbladder via a minimally invasive approach

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy (LC)
Description: Removal of the gallbladder via a minimally invasive approach

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy (LC)
Description: Removal of the gallbladder via a minimally invasive approach
Study: NCT01719120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
Study: NCT03722212

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: METAglut1
Description: A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: METAglut1
Description: A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
Study: NCT00683449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 1
Description: IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 placebo
Description: i.v. infusion of placebo for 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 2
Description: i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 3
Description: i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
Study: NCT02503462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
Study: NCT03488940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent group
Description: Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.
Study: NCT02279329

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Helium MRI
Description: Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study: NCT01361529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLP,dose escalation,MTD
Description: dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
Study: NCT01202110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT01835990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPCs
Description: devices that pneumatically compress the leg, resulting in increased venous blood flow.
Study: NCT01469052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (20 mg twice a day) in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (15 mg once a day) in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
Study: NCT03008590

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: One 4.5 mg capsule each evening

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: One 4.5 mg capsule each evening

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One capsule each evening

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One capsule each evening
Study: NCT03492775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Study: NCT01884285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: AZD8186 monotherapy
Description: The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: AZD8186 monotherapy
Description: Part B will be at a dose(s) and schedule(s) at or below from Part A
Study: NCT02387034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Description: Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.

Intervention type: OTHER
Group type: OTHER
Intervention: General advice
Description: Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
Study: NCT00867360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU-486)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication
Study: NCT03066479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Wearable activity \& sleep tracker.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSA questionnaire
Description: Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: All participants will be undergoing a sleep study as part of their clinical care.
Study: NCT02722798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Doses may be titrated to achieve the target peak serum phosphorus range
Study: NCT00685464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intracoronary
Study: NCT00662272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone vaccine with JVRS-100 adjuvant
Description: One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone vaccine
Description: One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone vaccine
Description: One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
Study: NCT04409119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIS/LBB pacing
Description: 3830 lead to HIS or LBB
Study: NCT04417348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinoic acid
Description: To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Retinoic acid
Description: To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
Study: NCT00746486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide placebo
Description: One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
Study: NCT05651698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMan Intervention group
Description: The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
Study: NCT03141151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH: Healthy Bodies
Description: Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COACH: Strong Minds
Description: School Readiness Intervention focusing on literacy and parent skills
Study: NCT02162615

Intervention type: DEVICE
Intervention: Restorelle Direct Fix A

Intervention type: DEVICE
Intervention: Restorelle Direct Fix P

Intervention type: PROCEDURE
Intervention: Native Tissue Repair Anterior

Intervention type: PROCEDURE
Intervention: Native Tissue Repair Posterior
Study: NCT02621190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: 25mg/m2 q3w